Assessment of the efficiency of the local application of hemostatic drug Geprocel in the treatment of patients with deep burns

Yunusov O T, Sadikov R A, Tagaev K R, Hakimov E A, Babur Shakirov

Abstract


The work is based on the analysis of the treatment results of 35 patients with burn trauma (10 women and 25 men) aged 15 to 55 years who were treated in the burn department of Republican Scientific Centre of Urgent Medical Aid (RSCUMA) between 2017 and 2018. In this study, we report on the use of the hemostatic preparation Geprocel with an autodermoplasty on a wound after necroectomy with subsequent autodermoplasty in all cases contributed to the complete healing of donor sites for 7 days, and the complete engraftment of the skin autotransplant with full recovery of the defect by 12 days after surgery. This preliminary data suggests the potential role of Geprocel in the clinical management of burn treatment.The work is based on the analysis of the treatment results of 35 patients with burn trauma (10 women and 25 men) aged 15 to 55 years who were treated in the burn department of Republican Scientific Centre of Urgent Medical Aid (RSCUMA) between 2017 and 2018. In this study, we report on the use of the hemostatic preparation Geprocel with an autodermoplasty on a wound after necroectomy with subsequent autodermoplasty in all cases contributed to the complete healing of donor sites for 7 days, and the complete engraftment of the skin autotransplant with full recovery of the defect by 12 days after surgery. This preliminary data suggests the potential role of Geprocel in the clinical management of burn treatment.


Keywords


Burn trauma; Haemostatic medications; Geprocel; Intravascular coagulation syndrome; Surgical treatments.

Full Text:

PDF


DOI: https://doi.org/10.5281/zenodo.2558592

Abstract - 141; PDF | 31 | times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Yunusov O.T., Sadikov R.A., Tagaev K.R., Hakimov E.A., Babur Shakirov



Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.